In vivo myeloproliferative diseases induced by FMS like tyrosine kinase 3-internal tandem duplications (FLT3-ITD), a mutation present in approximately 30% of AML patients, were compromised by deletion of SHP-1 (Reich et al., 2020). This evidence concerns the gene NR0B2 and acute myeloid leukemia.